Medicus Pharma shares surge 15.98% after-hours on positive Phase 2 SkinJect data showing 73% clinical clearance.
ByAinvest
Tuesday, Mar 10, 2026 4:03 pm ET1min read
MDCX--
Medicus Pharma (NASDAQ:MDCX) surged 16.0% in after-hours trading following the release of positive Phase 2 data for its SkinJect microneedle platform in basal cell carcinoma, which demonstrated 73% clinical clearance in the 200-µg cohort, and the announcement of its CEO’s participation in the Longwood Miami CEO Forum. The trial results highlighted SkinJect’s efficacy beyond placebo effects, reinforcing its potential as a non-surgical treatment and advancing regulatory discussions. Concurrently, the CEO’s focus on AI-enabled drug development at the forum underscored the company’s innovation in streamlining clinical trials, attracting investor optimism. These developments collectively drove the sharp post-market rally, reflecting confidence in Medicus’ therapeutic pipeline and strategic advancements.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet